Globus Medical, Inc. $GMED Stake Lifted by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 24.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,173 shares of the medical device company’s stock after purchasing an additional 14,412 shares during the period. Illinois Municipal Retirement Fund owned about 0.05% of Globus Medical worth $5,481,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Washington Trust Advisors Inc. boosted its position in Globus Medical by 116.8% during the second quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock valued at $3,556,000 after purchasing an additional 24,250 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Globus Medical during the 2nd quarter worth approximately $1,858,000. WCM Investment Management LLC bought a new stake in shares of Globus Medical during the 1st quarter worth approximately $16,965,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Globus Medical in the 2nd quarter valued at approximately $7,941,000. Finally, Congress Asset Management Co. boosted its holdings in shares of Globus Medical by 6.6% in the 3rd quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock valued at $27,041,000 after buying an additional 22,401 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GMED shares. Wall Street Zen lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. UBS Group assumed coverage on Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective for the company. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday, November 6th. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $96.08.

Read Our Latest Stock Report on Globus Medical

Insider Activity

In other Globus Medical news, Director Ann D. Rhoads sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director directly owned 35,384 shares in the company, valued at $3,007,640. The trade was a 12.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen T. Zarrilli sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 101,666 shares of company stock worth $7,970,017. 18.38% of the stock is currently owned by company insiders.

Globus Medical Price Performance

GMED opened at $72.02 on Monday. The business has a fifty day simple moving average of $76.56 and a 200 day simple moving average of $82.71. Globus Medical, Inc. has a 1 year low of $70.39 and a 1 year high of $101.40. The company has a market capitalization of $9.54 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 1.12 and a beta of 0.98.

Globus Medical (NYSE:GMED – Get Free Report) last posted its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. The company’s revenue was down .7% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts anticipate that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.

Globus Medical Profile

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Recommended Stories

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.